You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Les traitements par chimiothérapie et autres traitements systémiques pourraient être modifiés en raison de la COVID-19. Vous trouverez de plus amples renseignements à la page Traitements systémiques pendant la pandémie de la COVID-19.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Les renseignements du Formulaire de médicaments s’adressent aux professionnels de la santé. Il ne s’agit pas d’un avis médical. Certains des renseignements, y compris ceux sur le financement des médicaments anticancéreux, ne s’appliquent pas à tous les patients. Les plans de traitement du cancer sont propres à chaque patient. Si vous êtes un patient, veuillez parler avec votre équipe soignante pour comprendre comment ces renseignements s’appliquent à vous.

A - Regimen Name

TEMS Regimen

Disease Site
Genitourinary - Renal Cell / Kidney


Regimen Category
Evidence-Informed :

Regimen is considered appropriate as part of the standard care of patients; meaningfully improves outcomes (survival, quality of life), tolerability or costs compared to alternatives (recommended by the Disease Site Team and national consensus body e.g. pan-Canadian Oncology Drug Review, pCODR).  Recommendation is based on an appropriately conducted phase III clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use.

Rationale and Uses

Treatment of metastatic renal cell carcinoma. It is recommended and funded for first-line, poor-risk (defined by Mekhail criteria) metastatic renal cell cancer.

Supplementary Public Funding

New Drug Funding Program (Temsirolimus - Metastatic Renal Cell Carcinoma)

B - Drug Regimen

25 mg IV Weekly



back to top
C - Cycle Frequency


Until disease progression or unacceptable toxicity

D - Premedication and Supportive Measures

Antiemetic Regimen:


Other Supportive Care:

  • Diphenhydramine 25 to 50mg IV should be given 30 minutes before the start of the temsirolimus infusion.
E - Dose Modifications

Doses should be modified according to the protocol by which the patient is being treated. The following recommendations have been adapted from clinical trials or product monographs and could be considered.

Do not administer if bilirubin > 1.5 x ULN.




Dosage with toxicity

Toxicity and Grade



Pneumonitis (grade 1 or 2)

Hold until ≤ grade 1; may continue if asymptomatic. Consider steroids.

Consider dose reduction (5mg/week)

Pneumonitis (grade 3 or 4)

Discontinue, consider steroids

Discontinue permanently

Intolerable grade 2 non-hematological

May continue AND

Reduce by 5mg/week*

Grade 3 or 4 non-hematological

Hold until recovered to ≤ grade 2 AND

Reduce by 5mg/week*

Platelet < 75 x 109/L and/or ANC < 1 x 109/L

Hold until recovery to ≥ 75 x 109/L and  1 x 109/L AND

Reduce by 5mg/week*

*Minimum dose is 15mg/week  
Grade Action
Grade 1 or 2
  • Stop the infusion and observe the patient for at least 30-60 minutes.
  • If deemed appropriate by the physician, temsirolimus may be resumed. 
  • Administer a H1-receptor antagonist if one was not previously administered and/or a H2-receptor antagonist, such as famotidine 20mg IV or ranitidine 50mg IV, approximately 30 minutes before restarting the infusion.
  • Restart at a slower rate of up to 60 minutes.
Grade 3 or 4
  • Stop the infusion. Treat symptoms with antihistamines, antipyretics, beta-agonists and/or corticosteroids as appropriate.  Consider discontinuing temsirolimus treatment.

Hepatic Impairment

 Hepatic metabolism / excretion is significant.








Caution. Dose at 15mg


>1 - 1.5 x ULN

Caution. Dose at 15mg

Moderate to severe


>1.5 x ULN

Do not treat.

Renal Impairment

Use with caution.  No formal studies have been performed in renally impaired patients.  Dose adjustment may not be required since <5% of the dose is excreted in the urine.  Temsirolimus use in hemodialysis was described in a case series.


F - Adverse Effects

Refer to temsirolimus drug monograph(s) for additional details of adverse effects


Very common (≥ 50%)

Common (25-49%)

Less common (10-24%)

Uncommon (< 10%),

but may be severe or life-threatening

  • Hyperglycemia
  • Hyperlipidemia
  • ↑ LFTs (may be severe)
  • Creatinine increased (may be severe)
  • Fatigue


  • Rash (may be severe)
  • Edema (may be severe)
  • Mucositis
  • Nausea and vomiting
  • Anorexia
  • Infection (including opportunistic)
  • Cough, dyspnea
  • Diarrhea
  • Hemorrhage (may be severe)
  • Abnormal electrolytes


  • Abdominal pain
  • Constipation
  • Musculoskeletal pain
  • Myelosuppression
  • Nail changes
  • Dysguesia
  • Insomnia
  • Hypersensitivity
  • Venous thromboembolism
  • GI perforation
  • Delayed wound healing
  • QT interval prolonged
  • Rhabdomyolysis and ↑ CPK
  • Seizure
  • Interstitial lung disease
  • Secondary malignancy
G - Interactions

Refer to temsirolimus drug monograph(s) for additional details

  • Avoid concomitant usage with CYP3A4/5 inducers or strong CYP3A4 inhibitors. If the strong CYP3A4 inhibitor cannot be discontinued, consider temsirolimus dose reduction (to 12.5mg /week).
  • Caution and monitor for toxicity with CYP3A4/5, CYP2D6 and Pgp substrates
  • Extreme caution with anticoagulants due to increased risk of CNS bleeding in patients with CNS tumours
  • Caution with ACE inhibitors or calcium channel blockers due to increased risk of angioneurotic edema
  • Avoid QT prolonging drugs if possible
H - Drug Administration and Special Precautions

Refer to temsirolimus drug monograph(s) for additional details


  • Inject supplied diluent (contains polysorbate 80 and PEG 400) into the drug vial and then dilute further in 250mL Normal Saline, infuse over 30 -60 minutes. Avoid excessive shaking as this may cause foaming.
  • To decrease di-(2-ethylhexyl) phthalate (DEHP) leaching or avoid excessive drug loss, materials used in administration must be composed of glass, polyolefin or polyethylene.  Use a non-PVC non-DEHP tubing, including an in-line polyethersulfone filter ≤ 5 microns.  A polyethersulfone end-filter (0.2 to 5 microns) may be added if the administration set does not have an in-line filter component.  The use of both an in-line and end-filter is not recommended.
  • The drug concentrate-diluent mixture is stable for up to 24 hours at room temperature and protected from light. The final diluted drug solution should be completely administered within 6 hours from the time that the concentrate-diluent mixture is added to the Normal Saline bag.
  • Keep unopened drug and diluent vials refrigerated (2-8°C); do not freeze.
  • Protect the drug and diluted solutions from light.  Do not use if drug is discoloured or if particulates are present.


  • patients with known hypersensitivity to this sirolimus, temsirolimus, or any ingredients in the formulation
  • patients with elevated bilirubin (> 1.5 x ULN)

Other Warnings/Precautions:

  • patients with pre-existing or at risk of prolonged QTc
  • patients with brain metastases (increased risk of bleeding)
  • patients who have known hypersensitivity to an antihistamine or cannot receive an antihistamine for other medical reasons
  • patients on anticoagulants or who have had recent surgery
  • avoid use of live vaccines
  • Temsirolimus should not be used in pregnancy.  Adequate contraception should be used by both sexes during treatment, and for at least 3 months after the last dose.
  • Breastfeeding is not recommended


I - Recommended Clinical Monitoring

Recommended Clinical Monitoring

  • CBC; baseline and weekly
  • Lipids and fasting glucose; baseline and routine
  • Liver function tests; baseline and regular (every 2 weeks)
  • Renal function tests & electrolytes; baseline and regular (every 2 weeks)
  • Routine assessment for signs and symptoms of fatigue, hyperglycemia, bleeding, pneumonitis, fluid retention, skin toxicity, infections, mucositis, delayed wound healing, infusion reactions, rhabdomyolysis (especially with statins); regular
  • Grade toxicity using the current NCI-CTCAE (Common Terminology Criteria for Adverse Events) version

Suggested Clinical Monitoring

  • Radiology (screening for ILD); baseline and periodic

back to top
J - Administrative Information

Approximate Patient Visit
1 to 1.5 hours
Pharmacy Workload (average time per visit)
17.283 minutes
Nursing Workload (average time per visit)
39.167 minutes
K - References

Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. N Engl J Med 2007;356:2271-81.

Mekhail TM, Abou-Jawde RM, BouMerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23:832-41.

Temsirolimus drug monograph,  Ontairo Health (Cancer Care Ontario).

July 2020 Modified Drug administration section

back to top
M - Disclaimer

Regimen Abstracts
A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.
Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph.  Full regimen monographs will be published for each ST-QBP regimen as they are developed.
Regimen Monographs
Refer to the New Drug Funding Program or Ontario Public Drug Programs websites for the most up-to-date public funding information.
The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.
The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.
Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.
While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.
CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.